RxDoctor Payments Data

Daniel Yarrish, MD

Internal Medicine · Salt Lake City, UTNPI 1235240110

Payments from drug & device makers

$889in general payments, 2019–2025

Across 46 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$197
  • Abbott$102
  • Novo Nordisk$93
  • Pfizer$85
  • GSK$46
  • Astellas Pharma US Inc$41
  • plus $326 from 14 others

What the payments were for

  • Food & beverage$889100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$889 in reported general payments places this provider in the 70th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$124,217
Medicare patients
356
Services billed
1,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$183,039
OzempicSemaglutide117$145,754
JardianceEmpagliflozin47$60,289
MounjaroTirzepatide42$57,735
XareltoRivaroxaban58$57,250
TrulicityDulaglutide27$45,431
FarxigaDapagliflozin Propanediol45$43,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$36,458
MyrbetriqMirabegron46$31,912
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$26,513
ArexvyRsvpref3 Antigen/As01e/Pf76$22,516
JanuviaSitagliptin Phosphate19$21,664
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$17,092
WegovySemaglutide11$16,973
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$12,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$183,039194 claims
Novo NordiskOzempic, Wegovy$93$162,728128 claims
Lilly USA, LLCMounjaro, Trulicity$13$103,16569 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta$46$66,242130 claims
Johnson & JohnsonXarelto$18$57,25058 claims
AstraZenecaFarxiga$37$43,37645 claims
MerckJanuvia, Janumet Xr, Janumet$30$35,07642 claims
Astellas Pharma US IncMyrbetriq$41$31,91246 claims
Sumitomo Pharma America, Inc.Gemtesa$15$8,54119 claims
AbbVieSynthroid$197$4,47486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →